Screenshot of the carebaredx homepage as of 2026-05-08 — Screenshot of Care Bare Rx website as of 2026-05-08

Care Bare Rx GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: Care Bare Rx
Author: RangeYourself

Care Bare Rx review, semaglutide from $199/mo, tirzepatide from $199/mo. Cash-pay shoppers focused on the lowest defensible price. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-07-25

Quick take

Care Bare Rx is compounded semaglutide and tirzepatide, priced as flat low monthly, minimal add-ons. Best for: Cash-pay shoppers focused on the lowest defensible price. Watch out for: Lighter clinical model, confirm refill cadence and prescriber availability

Pricing summary

Price verified: 2026-07-25 (checked against the provider’s public pricing surface)
All-in monthly cost: $199/month (medication included), flat monthly rate
Semaglutide: From $199/mo
Tirzepatide: From $199/mo
Compounded vs brand-name: Compounded only
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Not shown publicly on carebarerx.com, the weight-loss product page (carebarerx.com/products/weight-loss-medications) describes oral and injectable compounded semaglutide/tirzepatide formats with no per-dose price breakdown; only the flat 'From $199/mo' starting price is shown anywhere on the site. Verified 2026-07-25.
Refund policy: Cancel anytime; no refund on dispensed compounds
States served: All states except Louisiana

See Care Bare Rx pricing →

Choose Care Bare Rx if

You want a low monthly price with compounded medication included
You're comfortable with async-only clinical communication
You don't need a heavy coaching layer
You want a no-frills, transparent monthly bill

Skip Care Bare Rx if

You want active coaching or video consults.

Contraindications and clinical notes

Standard GLP-1 contraindications. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

Verified programs that cost less than Care Bare Rx

Care Bare Rx’s own verified figure is $199/mo (flat monthly rate). Every program below carries a lower all-in monthly price that we verified on the provider’s own pricing page, ranked lowest first as of September 21, 2026.

1.Embody
$69/mo (limited-time promo), verified September 17, 2026
See pricing →
2.Strut Health
$99/mo (sublingual/oral starting price), verified August 21, 2026
See pricing →
3.Trimi
$99/mo (annual-plan rate), verified August 21, 2026
See pricing →
4.HealthRX
$99/mo (12-month plan rate), verified September 16, 2026
See pricing →
5.bmiMD
$119/mo (12-month plan rate), verified September 3, 2026
See pricing →

Prices are each provider’s own published all-in monthly figure at the plan term shown, verified on the date listed. RangeYourself may earn a commission from some programs; that can only break an exact tie between verified equals and never changes the price order.

How Care Bare Rx compares

Frequently asked questions

How much does Care Bare Rx cost per month?

Care Bare Rx's lowest verified rate is $199/month with compounded medication included. Semaglutide: From $199/mo; tirzepatide: From $199/mo. Not shown publicly on carebarerx.com, the weight-loss product page (carebarerx.com/products/weight-loss-medications) describes oral and injectable compounded semaglutide/tirzepatide formats with no per-dose price breakdown; only the flat 'From $199/mo' starting price is shown anywhere on the site. Verified 2026-07-25.

Does Care Bare Rx accept insurance?

Care Bare Rx publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does Care Bare Rx serve?

Care Bare Rx ships medication to all US states except Louisiana, where state telehealth-prescribing rules currently restrict the program.

Is Care Bare Rx compounded or brand-name?

Care Bare Rx prescribes compounded semaglutide and tirzepatide via state-licensed 503A pharmacies or 503B outsourcing facilities. Compounded medication is not individually FDA-approved. The shortage-era compounding pathway ended after the FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so compounding now proceeds under the ordinary rules for individual patients.

What's the catch with Care Bare Rx?

Lighter clinical model, confirm refill cadence and prescriber availability Avoid if: you want active coaching or video consults.

Related guides

Care Bare Rx availability by state

GLP-1 programs in California , where Care Bare Rx ships and how it stacks up locally.
GLP-1 programs in Texas , where Care Bare Rx ships and how it stacks up locally.
GLP-1 programs in Florida , where Care Bare Rx ships and how it stacks up locally.
GLP-1 programs in New York , where Care Bare Rx ships and how it stacks up locally.
GLP-1 programs in Illinois , where Care Bare Rx ships and how it stacks up locally.

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers verified on 2026-07-25 and may change.